The present invention relates to 2-aminoquinolines of formula I
wherein R1, R2 and R3 are as defined in the specification, as 5-HT5A receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of CNS disorders.
QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS
申请人:F. Hoffmann-La Roche AG
公开号:EP2195296A1
公开(公告)日:2010-06-16
US8399674B2
申请人:——
公开号:US8399674B2
公开(公告)日:2013-03-19
[EN] QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE QUINOLINE UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR 5HT5A
申请人:HOFFMANN LA ROCHE
公开号:WO2009040290A1
公开(公告)日:2009-04-02
The present invention relates to 2-Aminoquinoline derivatives which are represented by the general formula I wherein R1, R2 and R3 are as defined in the specification as 5-HT5A receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments.
QUINOLINES
申请人:Kolczewski Sabine
公开号:US20090088451A1
公开(公告)日:2009-04-02
The present invention relates to 2-aminoquinolines of formula I
wherein R
1
, R
2
and R
3
are as defined in the specification, as 5-HT
5A
receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of CNS disorders.